Avid Bioservices expects new contractual commitments in the coming weeks and months after raising more than $20m and completing its transition to a dedicated CDMO, says CEO.
Scientist.com is working to implement an improved contractual landscape ahead of GDPR implementation in May, in order to ensure global compliance among sponsors and CROs.
Lonza has inked a biologics deal with Denali to make neurodegenerative disease therapies, offering the Californian firm opportunity to have production “on their back doorstep.”
Vetter is talking with customers to create a “stable financial plan” that will justify the manufacturer’s previously announced $320m investment for a new facility, which is not expected to break ground before 2022.
The San Diego-CA-based contract research, development, and manufacturing organization (CDMO), BioDuro, has announced a cooperation agreement with Porton Pharma Solutions.
Impax Laboratories has sold its CorePharma facilities and equipment to a group of industry investors which aim to reestablish the company as a "preferred partner of choice," says new CEO.
Avista Pharma Solutions, Inc. has acquired Solid Form Solutions, Ltd. to provide customers with a broader suite of services as a single company, says CEO.
Paragon Bioservices plans to open a new 150,000 square-foot facility to help fulfill a growing demand for the company’s gene therapy manufacturing services, says CEO.
Almac Group has invested £30m ($41.65) to expand its clinical and commercial drug supplies capabilities at its European Campus in Ireland as it prepares for the UK’s exit from the EU.
Ipca Laboratories, a fully-integrated Indian pharmaceutical company, has purchased an NC-based CMO in a $9.65m deal that will enable it to manufacture small volume APIs for the US market.
